UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 40

Sortiert nach

Perspectives on the clinical development of immunotherapy in prostate cancer

Asian journal of andrology, 2018-05, Vol.20 (3), p.253-259

2018

Link zum Volltext

Verfügbarkeit prüfen

First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case report

Frontiers in oncology, 2023-03, Vol.13, p.1126476

2023

Link zum Volltext

Verfügbarkeit prüfen

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer

Frontiers in oncology, 2021-03, Vol.10, p.581801-581801

2021

Link zum Volltext

Verfügbarkeit prüfen

Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute

Journal of clinical oncology, 2022-06, Vol.40 (17), p.1949-1957

2022

Link zum Volltext

Verfügbarkeit prüfen

Docetaxel extravasation: Pathologic correlation and treatment with intralesional steroids

JAAD Case Reports, 2017-07, Vol.3 (4), p.322-325

2017

Link zum Volltext

Verfügbarkeit prüfen

The evolving role of immunotherapy in prostate cancer

Current opinion in oncology, 2016-05, Vol.28 (3), p.232-240

2016

Link zum Volltext

Verfügbarkeit prüfen

Phase II evaluation of combination immunotherapy with CV301, N-803, bintrafusp alfa, and M9241 in patients with advanced small bowel and colorectal cancers

Journal of clinical oncology, 2023-02, Vol.41 (4_suppl), p.116-116

2023

Link zum Volltext

Verfügbarkeit prüfen

Association of 18 F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4600-4600

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent/metastatic (R/M) HPV-associated cancers (HPV-C)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.2628-2628

2023

Link zum Volltext

Verfügbarkeit prüfen

Phase 2 study of bintrafusp alfa in recurrent/metastatic olfactory neuroblastoma

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS6116-TPS6116

2023

Link zum Volltext

Verfügbarkeit prüfen

A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS5101-TPS5101

2023

Link zum Volltext

Verfügbarkeit prüfen

Anaplastic features (AnaF) and DNA-damage repair pathway (DDR) mutations in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2021-02, Vol.39 (6_suppl), p.92-92

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase II evaluation of the combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16+ malignancies

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2518-2518

2022

Link zum Volltext

Verfügbarkeit prüfen

A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS4607-TPS4607

2023

Link zum Volltext

Verfügbarkeit prüfen

Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib + nivolumab +/- ipilimumab

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16506-e16506

2023

Link zum Volltext

Verfügbarkeit prüfen

FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e16573-e16573

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.4571-4571

2023

Link zum Volltext

Verfügbarkeit prüfen

Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.207-207

2023

Link zum Volltext

Verfügbarkeit prüfen

A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.TPS5096-TPS5096

2021

Link zum Volltext

Verfügbarkeit prüfen

Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.e17044-e17044

2021

Link zum Volltext

Verfügbarkeit prüfen

Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e17033-e17033

2022

Link zum Volltext

Verfügbarkeit prüfen

Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.93-93

2022

Link zum Volltext

Verfügbarkeit prüfen

PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC)

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e17046-e17046

2022

Link zum Volltext

Verfügbarkeit prüfen

The immunocytokine M9241 in the treatment of prostate cancer (PCa): Clinical and immune data from a phase 1 study

Journal of clinical oncology, 2022-02, Vol.40 (6_suppl), p.127-127

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 40

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(39)
Berichte
(1)

Sprache

Englisch
(40)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(13)
Humans
(9)
Life Sciences & Biomedicine
(8)
Oncology
(6)
Immunotherapy
(5)
Male
(5)
Multidisciplinary Sciences
(5)
Prostate Cancer
(5)
Science & Technology - Other Topics
(5)
Animals
(3)
Biodiversity
(3)
Female
(3)
Metastasis
(3)
Middle Aged
(3)
Tumors
(3)
Adult
(2)
Aged
(2)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Biology And Life Sciences
(2)
Cancer Therapies
(2)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

3 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Perspectives on the clinical development of immunotherapy in prostate cancer

First-line pembrolizumab plus androgen deprivation therapy for locally advanced microsatellite instability-high prostate cancer in a patient with Muir-Torre syndrome: A case report

Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute

Docetaxel extravasation: Pathologic correlation and treatment with intralesional steroids

The evolving role of immunotherapy in prostate cancer

Phase II evaluation of combination immunotherapy with CV301, N-803, bintrafusp alfa, and M9241 in patients with advanced small bowel and colorectal cancers

Association of 18 F-FDG PET characteristics and survival outcomes using whole body tumor analysis in patients (pts) with metastatic genitourinary (GU) malignancies

Phase I evaluation of PRGN-2009 alone and in combination with bintrafusp alfa in patients (pts) with recurrent/metastatic (R/M) HPV-associated cancers (HPV-C)

Phase 2 study of bintrafusp alfa in recurrent/metastatic olfactory neuroblastoma

A study of prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging (18F-DCFPyL)

Anaplastic features (AnaF) and DNA-damage repair pathway (DDR) mutations in metastatic castration-resistant prostate cancer (mCRPC)

Phase II evaluation of the combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16+ malignancies

A phase II study of olaparib (AZD2281) in patients (Pts) with metastatic/advanced urothelial carcinoma and other genitourinary (GU) tumors with DNA-repair defects

Comparison of peripheral blood markers in predicting the occurrence of immune-related adverse events in patients with metastatic genitourinary cancer treated with cabozantinib + nivolumab +/- ipilimumab

FDG PET/CT and NaF PET/CT imaging quantification of osseous metastatic lesions in patients with metastatic genitourinary (mGU) cancer and their association with survival outcomes

A phase I study of bintrafusp alfa and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in patients with metastatic genitourinary (GU) malignancies

Effects of docetaxel on circulating immune cell subsets and association with outcomes in metastatic castration-sensitive prostate cancer

A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC)

Patients with undetectable PSA 2 years after docetaxel for metastatic castration sensitive prostate cancer (mCSPC)

Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer: A phase I study

Safety evaluation of M9241 in combination with docetaxel in metastatic prostate cancer

PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC)

The immunocytokine M9241 in the treatment of prostate cancer (PCa): Clinical and immune data from a phase 1 study

Aktive Filter

Suchergebnisse filtern